{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:22:33Z","timestamp":1790400153996,"version":"4.1.0"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,3,9]],"date-time":"2015-03-09T00:00:00Z","timestamp":1425859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Scientific Research (C) from the Ministry for Education, Culture, Sports, Science and Technology of Japan","award":["24890080"],"award-info":[{"award-number":["24890080"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunology"],"published-print":{"date-parts":[[2015,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Toll\u2010like receptor (\n                    <jats:styled-content style=\"fixed-case\">TLR<\/jats:styled-content>\n                    ) agonists have been shown to have anti\u2010tumour activity in basic research and clinical studies. However,\n                    <jats:styled-content style=\"fixed-case\">TLR<\/jats:styled-content>\n                    agonist monotherapy does not sufficiently eliminate tumours. Activation of the innate immune response by\n                    <jats:styled-content style=\"fixed-case\">TLR<\/jats:styled-content>\n                    agonists is effective at driving adaptive immunity via interleukin\u201012 (\n                    <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\n                    \u201012) or\n                    <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\n                    \u20101, but is counteracted by the simultaneous induction of immunosuppressive cytokines and other molecules, including\n                    <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\n                    \u201010, transforming growth factor\u2010\n                    <jats:italic>\u03b2<\/jats:italic>\n                    , and indoleamine 2,3\u2010dioxygenase (\n                    <jats:styled-content style=\"fixed-case\">IDO<\/jats:styled-content>\n                    ). In the present study, we evaluated the anti\u2010cancer effect of the\n                    <jats:styled-content style=\"fixed-case\">TLR<\/jats:styled-content>\n                    7 agonist, imiquimod (\n                    <jats:styled-content style=\"fixed-case\">IMQ<\/jats:styled-content>\n                    ), in the absence of\n                    <jats:styled-content style=\"fixed-case\">IDO<\/jats:styled-content>\n                    activity. The administration of\n                    <jats:styled-content style=\"fixed-case\">IMQ<\/jats:styled-content>\n                    in\n                    <jats:styled-content style=\"fixed-case\">IDO<\/jats:styled-content>\n                    knockout (\n                    <jats:styled-content style=\"fixed-case\">KO<\/jats:styled-content>\n                    ) mice inoculated with tumour cells significantly suppressed tumour progression compared with that in wild\u2010type (\n                    <jats:styled-content style=\"fixed-case\">WT<\/jats:styled-content>\n                    ) mice, and improved the survival rate. Moreover, injection with\n                    <jats:styled-content style=\"fixed-case\">IMQ<\/jats:styled-content>\n                    enhanced the tumour antigen\u2010specific T helper type 1 response in\n                    <jats:styled-content style=\"fixed-case\">IDO<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">KO<\/jats:styled-content>\n                    mice with tumours. Combination therapy with\n                    <jats:styled-content style=\"fixed-case\">IMQ<\/jats:styled-content>\n                    and an\n                    <jats:styled-content style=\"fixed-case\">IDO<\/jats:styled-content>\n                    inhibitor also significantly inhibited tumour growth. Our results indicated that the enhancement of\n                    <jats:styled-content style=\"fixed-case\">IDO<\/jats:styled-content>\n                    expression with\n                    <jats:styled-content style=\"fixed-case\">TLR<\/jats:styled-content>\n                    agonists in cancer treatment might impair host anti\u2010tumour immunity while the inhibition of\n                    <jats:styled-content style=\"fixed-case\">IDO<\/jats:styled-content>\n                    could enhance the therapeutic efficacy of\n                    <jats:styled-content style=\"fixed-case\">TLR<\/jats:styled-content>\n                    agonists via the increase of T helper type 1 immune response.\n                  <\/jats:p>","DOI":"10.1111\/imm.12413","type":"journal-article","created":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T10:36:26Z","timestamp":1413455786000},"page":"621-630","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Inhibition of indoleamine 2,3\u2010dioxygenase activity enhances the anti\u2010tumour effects of a\n                    <scp>T<\/scp>\n                    oll\u2010like receptor 7 agonist in an established cancer model"],"prefix":"10.1111","volume":"144","author":[{"given":"Hiroyasu","family":"Ito","sequence":"first","affiliation":[{"name":"Department of Informative Clinical Medicine First Department of Internal Medicine Gifu University Graduate School of Medicine Gifu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Informative Clinical Medicine First Department of Internal Medicine Gifu University Graduate School of Medicine Gifu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Arioka","sequence":"additional","affiliation":[{"name":"Department of Informative Clinical Medicine First Department of Internal Medicine Gifu University Graduate School of Medicine Gifu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuniaki","family":"Saito","sequence":"additional","affiliation":[{"name":"Human Health Sciences Graduate School of Medicine and Faculty of Medicine Kyoto University Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Seishima","sequence":"additional","affiliation":[{"name":"Department of Informative Clinical Medicine First Department of Internal Medicine Gifu University Graduate School of Medicine Gifu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,3,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1863"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210910"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0904173"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21583"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901150"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.08.120"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1003"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030633"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.189.9.1363"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401073"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020052"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003151"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI34823"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.7.3892"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.9.5247"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2014.04.015"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep02559"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.2220\/biomedres.32.159"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.1.391"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706059104"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.126215"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195354"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900291"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0366-077X.2003.05626.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0955"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2522"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1414-x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxn046"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.158.8.3947"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0606399"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12274"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-407163"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902997"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116111"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0513-6"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2007.04.010"}],"container-title":["Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimm.12413","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imm.12413","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T05:11:05Z","timestamp":1696137065000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imm.12413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,9]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.1111\/imm.12413"],"URL":"https:\/\/doi.org\/10.1111\/imm.12413","archive":["Portico"],"relation":{},"ISSN":["0019-2805","1365-2567"],"issn-type":[{"value":"0019-2805","type":"print"},{"value":"1365-2567","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,9]]},"assertion":[{"value":"2014-06-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}